Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant RSV vaccine (CHO cells) in adults ≥60 years
ChiCTR2500110612Phase 3Not yet recruiting
- Sponsor
- Henan Center for Disease Control and Prevention
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus lower respiratory tract infection, respiratory syncytial virus disease (RSV) and pulmonary infection (2 arms), sponsored by Henan Center for Disease Control and Prevention. Primary endpoint: Incidence rate per person-year of first RT-PCR-confirmed RSV-A and/or RSV-B lower respiratory tract disease (LRTD). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus lower respiratory tract infectionrespiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on ChiCTR2500110612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110612.